Shire to take on hemophilia marketing with long-sought Baxalta buy

Baxalta ($BXLT) and its portfolio of hemophilia meds are finally destined to join the fold at Shire ($SHPG). Monday, the two companies announced a $32 billion tie-up after a months-long pursuit by the Dublin drugmaker. More from FiercePharma

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

COVID-19 vaccine makers' recent safety pledge continues to increase positive sentiment among Americans, new Harris Poll data say.

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.